← Ablatotech Vitals
Cardiology EvidenceDigest

Impact of Integrated Care Models on Outcomes in Patients with Heart Failure and Comorbid Chronic Kidney Disease

Cardiology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 5, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Integrated care models involving multispecialty, multidisciplinary teams that address both heart failure (HF) and comorbid chronic kidney disease (CKD) can reduce hospitalizations and clinic visits, optimize treatment, and potentially improve clinical outcomes. Emerging evidence supports coordinated management strategies that bridge cardiology and nephrology, emphasizing tailored therapies and close monitoring to mitigate the high morbidity and mortality associated with cardiorenal syndrome.

Clinical bottom line

Integrated care models involving multispecialty, multidisciplinary teams that address both heart failure (HF) and comorbid chronic kidney disease (CKD) can reduce hospitalizations and clinic visits, optimize treatment, and potentially improve clinical outcomes. Emerging evidence supports coordinated management strategies that bridge cardiology and nephrology, emphasizing tailored therapies and close monitoring to mitigate the high morbidity and mortality associated with cardiorenal syndrome.

What the evidence shows

Essa et al. (2022) demonstrated that multispecialty multidisciplinary input targeting comorbidities alongside treatment optimization in HF patients significantly reduced hospitalizations and outpatient clinic attendance. Their findings highlight the value of integrated care pathways that address the complex interplay between HF and CKD.

Savarese et al. (2025) analyzed cardiorenal outcomes and all-cause mortality in patients with comorbid HF and CKD across three countries in the CaRe Study. They confirmed that CKD presence markedly worsens prognosis in HF, underscoring the need for integrated management approaches to improve survival and reduce adverse events.

Greene et al. (2026) reviewed pathophysiological pathways linking HF and CKD and discussed therapeutic strategies. They emphasized that integrated care models facilitate individualized treatment plans, including guideline-directed medical therapy adjustments considering renal function, to optimize outcomes.

McCullough et al. (2016) provided evidence supporting goal-directed HF care in patients with CKD and end-stage renal disease, demonstrating that specialized programs can improve symptom control and reduce hospitalizations despite the challenges posed by renal impairment.

McEwan et al. (2022) projected the growing healthcare burden of cardiorenal disease in the United States and highlighted the potential impact of novel therapies within integrated care frameworks to alleviate this burden.

Although not specific to HF-CKD integration, Wheeler et al. (2026) showed that pharmacist-managed diabetes care in rural clinics improved clinical outcomes, suggesting that multidisciplinary involvement including pharmacists may enhance management of comorbid conditions common in cardiorenal patients.

Caveats and uncertainty

Most studies are observational or registry-based, limiting causal inference.

Variability in integrated care model design, team composition, and healthcare settings complicates generalizability.

Long-term outcome data and cost-effectiveness analyses remain sparse.

Optimal timing and intensity of interventions within integrated models require further clarification.

Barriers such as resource availability, communication challenges, and patient adherence may limit implementation.

How this may change practice

Clinicians should advocate for and participate in multidisciplinary teams that include cardiology, nephrology, pharmacy, nursing, and allied health to comprehensively manage HF patients with CKD.

Routine screening for CKD in HF patients and vice versa can facilitate early identification and integrated care planning.

Treatment regimens should be individualized considering renal function, balancing HF guideline-directed therapies with renal safety.

Health systems should develop protocols and pathways to support coordinated care transitions and follow-up.

Education and engagement of patients and caregivers remain critical to optimize adherence and self-management.

Future clinical trials and health services research should focus on defining best practices and evaluating integrated care models’ impact on outcomes and costs.


References

  1. Essa H, et al. Multispecialty multidisciplinary input into comorbidities along with treatment optimisation in heart failure reduces hospitalisation and clinic attendance. Open Heart 2022;9:e001979. DOI:10.1136/openhrt-2022-001979
  2. Savarese G, et al. Cardiorenal outcomes and all-cause mortality in patients with comorbid heart failure and chronic kidney disease across three countries (The CaRe Study). Eur Heart J 2025;46:1080. DOI:10.1093/eurheartj/ehaf784.1080
  3. Greene SJ, et al. Cardiorenal Disease Pathways and Treatment of Patients With Comorbid Heart Failure and Chronic Kidney Disease. JACC Heart Fail 2026;14:103179. DOI:10.1016/j.jchf.2026.103179
  4. McCullough PA, et al. Goal-Directed Heart Failure Care in Patients With Chronic Kidney Disease and End-Stage Renal Disease. JACC Heart Fail 2016;4:681-690. DOI:10.1016/j.jchf.2016.03.014
  5. McEwan P, et al. Cardiorenal disease in the United States: Future health care burden and potential impact of novel therapies. J Manag Care Spec Pharm 2022;28:213-225. DOI:10.18553/jmcp.2022.21385
  6. Wheeler SE, et al. Impact of Pharmacist-Managed Diabetes Care on Clinical Outcomes in Rural Health Clinics. Ann Pharmacother 2026;60:460-468. DOI:10.1177/10600280261446051

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team